POMDOCTOR LIMITED (POM) Cash Flow Statement
Where POM’s cash came from and went, 2025
December 31, 2025 · Chinese yuan- Cash from operations
- −CN¥148.5M
- Capital expenditures
- CN¥1.0M 0.3% of revenue
- Free cash flow
- −CN¥149.5M −37.4% margin
- Returned to shareholders
- —
- Change in cash
- CN¥1.9M cash at year-end CN¥9.6M
Cash from operations
−CN¥148.5M
Capital expenditures
−CN¥1.0M
Acquisitions & other
−CN¥600,000
Net borrowing (repayment)
+CN¥14.1M
Shares issued
+CN¥163.9M
Other financing
−CN¥24.1M
Currency & other
−CN¥1.9M
Change in cash
CN¥1.9M
Drawn to scale: where the cash came from and how it was used. Hover for values.
POM operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
POM cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | CN¥8.45B2016 | −CN¥148.5M2025 | — | |
| Capital expenditures | CN¥8.55B2016 | CN¥1.0M2025 | −63.4%/yr | |
| Free cash flow | −CN¥108.0M2016 | −CN¥149.5M2025 | — | |
| Free cash flow margin | −0.3%2016 | −37.4%2025 | −37.0 pts | |
| Operating cash flow / net income | 7.452016 | 0.032019 | −7.42 | |
| Stock-based compensation | CN¥02023 | CN¥16.4M2025 | — | |
| Share buybacks (net) | CN¥635.0M2016 | CN¥1.35B2018 | +45.8%/yr | |
| Capex / revenue | 27.3%2016 | 0.3%2025 | −27.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
POM cash flow by activity
OperatingInvestingFinancingChange in cash
POM net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
POM cash flow statement in Chinese yuan
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −CN¥130.9M | −CN¥37.4M | −CN¥36.9M | −CN¥19.8M | −CN¥96.2M | −CN¥256.5M | CN¥3.03B | CN¥398.0M | CN¥2.69B | CN¥1.13B |
| Depreciation & amortization | CN¥149,307 | CN¥134,510 | CN¥112,092 | CN¥0 | CN¥21.3M | CN¥20.9M | CN¥502.0M | CN¥5.97B | CN¥5.43B | CN¥5.58B |
| Stock-based compensation | CN¥16.4M | CN¥0 | CN¥0 | — | — | — | — | — | — | — |
| Change in working capital | −CN¥37.9M | CN¥17.5M | −CN¥12.6M | −CN¥1.4M | CN¥35.1M | CN¥200.6M | −CN¥1.96B | CN¥918.0M | CN¥2.08B | CN¥61.0M |
| Other non-cash items | CN¥3.8M | CN¥3.6M | CN¥3.6M | −CN¥774,449 | CN¥24.0M | CN¥152,011 | −CN¥1.48B | CN¥1.36B | −CN¥2.72B | CN¥1.67B |
| Cash from operating activities | −CN¥148.5M | −CN¥16.1M | −CN¥45.8M | −CN¥22.0M | −CN¥15.7M | −CN¥34.8M | CN¥85.0M | CN¥8.64B | CN¥7.48B | CN¥8.45B |
| Investing activities | ||||||||||
| Capital expenditures | −CN¥1.0M | −CN¥37,773 | −CN¥111,891 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | −CN¥7.59B | −CN¥7.58B | −CN¥8.55B |
| Investments (net) | — | −CN¥33,373 | −CN¥111,891 | CN¥0 | −CN¥500,000 | — | — | — | — | — |
| Acquisitions & other investing | −CN¥600,000 | CN¥37,773 | CN¥111,891 | — | CN¥0 | CN¥25,000 | CN¥8.0M | −CN¥240.0M | −CN¥350.0M | −CN¥6.95B |
| Cash from investing activities | −CN¥1.6M | −CN¥33,373 | −CN¥111,891 | — | −CN¥500,000 | CN¥25,000 | CN¥8.0M | −CN¥7.83B | −CN¥7.93B | −CN¥15.50B |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | −CN¥1.35B | −CN¥898.0M | −CN¥635.0M |
| Net borrowing (repayment) | CN¥14.1M | CN¥17.0M | CN¥52.3M | CN¥22.5M | CN¥5.4M | — | — | — | — | — |
| Shares issued | CN¥163.9M | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Other financing | −CN¥24.1M | CN¥0 | −CN¥2.3M | CN¥0 | CN¥0 | CN¥36.4M | −CN¥8.0M | CN¥1.13B | CN¥1.61B | CN¥1.83B |
| Cash from financing activities | CN¥153.9M | CN¥17.0M | CN¥50.1M | CN¥22.5M | CN¥5.4M | CN¥36.4M | −CN¥8.0M | −CN¥219.0M | CN¥717.0M | CN¥1.19B |
| Summary | ||||||||||
| Net change in cash | CN¥1.9M | CN¥846,596 | CN¥4.2M | CN¥474,664 | −CN¥10.7M | CN¥1.6M | CN¥12.0M | CN¥591.0M | CN¥263.0M | −CN¥5.87B |
| Cash at end of period | CN¥9.6M | CN¥7.7M | CN¥6.8M | CN¥2.6M | CN¥2.2M | CN¥12.9M | CN¥25.0M | CN¥1.78B | CN¥898.0M | CN¥635.0M |
| Free cash flow | −CN¥149.5M | −CN¥16.2M | −CN¥45.9M | −CN¥22.0M | −CN¥15.7M | −CN¥34.8M | CN¥85.0M | CN¥1.05B | −CN¥104.0M | −CN¥108.0M |
| Free cash flow margin | −37.4% | −4.7% | −15.1% | −9.0% | −7.3% | −24.6% | 0.2% | 2.9% | −0.3% | −0.3% |
| Capex / revenue | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 21.1% | 22.6% | 27.3% |
| Operating cash flow / net income | — | — | — | — | — | — | 0.03 | 21.72 | 2.78 | 7.45 |
| Jun '26 | Mar '20 | Dec '19 | Sep '19 | Jun '19 | Mar '19 | Dec '18 | Sep '18 | Jun '18 | Mar '18 | Dec '17 | Sep '17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −CN¥33.6M | CN¥45.0M | CN¥808.0M | CN¥365.0M | CN¥494.0M | CN¥363.0M | CN¥105.0M | CN¥233.0M | CN¥178.0M | CN¥136.0M | CN¥2.21B | CN¥305.0M |
| Depreciation & amortization | CN¥18,531 | CN¥1.38B | −CN¥265.0M | CN¥2.93B | CN¥257.0M | CN¥1.46B | CN¥1.46B | CN¥1.51B | CN¥1.50B | CN¥1.50B | CN¥1.43B | CN¥1.41B |
| Change in working capital | CN¥4.4M | CN¥710.0M | CN¥871.0M | CN¥10.51B | −CN¥11.63B | −CN¥1.71B | −CN¥1.38B | CN¥1.47B | CN¥483.0M | CN¥342.0M | CN¥709.0M | CN¥2.06B |
| Other non-cash items | CN¥30.7M | −CN¥1.05B | −CN¥1.51B | −CN¥9.45B | CN¥10.91B | CN¥930.0M | CN¥1.78B | −CN¥408.0M | CN¥207.0M | −CN¥477.0M | −CN¥2.55B | −CN¥996.0M |
| Cash from operating activities | CN¥1.5M | CN¥1.08B | −CN¥95.0M | CN¥4.36B | CN¥31.0M | CN¥1.04B | CN¥1.97B | CN¥2.81B | CN¥2.37B | CN¥1.50B | CN¥1.80B | CN¥2.78B |
| Investing activities | ||||||||||||
| Capital expenditures | −CN¥19,454 | −CN¥2.02B | CN¥0 | −CN¥3.39B | CN¥0 | −CN¥1.87B | −CN¥2.10B | −CN¥1.69B | −CN¥1.93B | −CN¥1.88B | −CN¥2.03B | −CN¥1.71B |
| Acquisitions & other investing | CN¥10,225 | −CN¥59.0M | −CN¥17.0M | −CN¥43.0M | CN¥6.0M | CN¥87.0M | −CN¥128.0M | −CN¥73.0M | −CN¥62.0M | CN¥23.0M | −CN¥96.0M | −CN¥119.0M |
| Cash from investing activities | −CN¥9,229 | −CN¥2.08B | −CN¥17.0M | −CN¥3.43B | CN¥6.0M | −CN¥1.79B | −CN¥2.23B | −CN¥1.76B | −CN¥1.99B | −CN¥1.86B | −CN¥2.12B | −CN¥1.83B |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | CN¥880.0M | — | −CN¥880.0M | CN¥569.0M | −CN¥1.13B | CN¥787.0M | −CN¥787.0M | CN¥305.0M | −CN¥667.0M |
| Shares issued | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Other financing | −CN¥682,220 | CN¥1.86B | CN¥2.0M | −CN¥942.0M | −CN¥1.0M | CN¥1.16B | −CN¥853.0M | CN¥1.38B | −CN¥1.24B | CN¥1.05B | −CN¥289.0M | CN¥385.0M |
| Cash from financing activities | −CN¥682,220 | CN¥1.86B | CN¥2.0M | −CN¥62.0M | −CN¥1.0M | CN¥275.0M | −CN¥284.0M | CN¥250.0M | −CN¥449.0M | CN¥264.0M | CN¥16.0M | −CN¥282.0M |
| Summary | ||||||||||||
| Net change in cash | CN¥1.9M | CN¥870.0M | −CN¥346.0M | CN¥864.0M | CN¥38.0M | −CN¥467.0M | −CN¥540.0M | CN¥1.29B | −CN¥71.0M | −CN¥91.0M | −CN¥305.0M | CN¥667.0M |
| Cash at end of period | CN¥1.9M | CN¥1.99B | CN¥25.0M | CN¥2.18B | CN¥316.0M | CN¥1.31B | CN¥1.78B | CN¥2.32B | CN¥1.03B | CN¥1.10B | CN¥898.0M | CN¥1.20B |
| Free cash flow | CN¥1.5M | −CN¥936.0M | −CN¥95.0M | CN¥969.0M | CN¥31.0M | −CN¥829.0M | −CN¥128.0M | CN¥1.12B | CN¥440.0M | −CN¥378.0M | −CN¥225.0M | CN¥1.07B |
| Free cash flow margin | 5.4% | −10.7% | −1.1% | 5.8% | 0.4% | −8.7% | −1.5% | 11.9% | 5.4% | −3.9% | −2.7% | 12.2% |
| Capex / revenue | 0.1% | 23.0% | 0.0% | 20.4% | 0.0% | 19.8% | 23.8% | 18.0% | 23.9% | 19.4% | 24.2% | 19.5% |
| Operating cash flow / net income | — | 24.00 | −0.12 | 11.93 | 0.06 | 2.88 | 18.75 | 12.04 | 13.30 | 11.04 | 0.81 | 9.11 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in Chinese yuan as reported; data from EODHD.
POM cash generation
In fiscal 2025 (ended December 31, 2025), POMDOCTOR LIMITED generated -CN¥148.5 million of cash from operations and spent CN¥1.0 million on capital expenditures, leaving free cash flow of -CN¥149.5 million, −37.4% of revenue. Cash and equivalents rose by CN¥1.9 million over the year.
Related: POM income statement, POM balance sheet. See the POM stock overview for the latest quote and news.
POM cash flow FAQ
What is POMDOCTOR LIMITED's free cash flow?
POMDOCTOR LIMITED's free cash flow was -CN¥149.5 million in fiscal 2025: -CN¥148.5 million of operating cash flow minus CN¥1.0 million of capital expenditures It was -CN¥16.2 million a year earlier..
How much cash does POMDOCTOR LIMITED generate from operations?
POMDOCTOR LIMITED generated -CN¥148.5 million of cash from operating activities in fiscal 2025.
How much does POMDOCTOR LIMITED spend on capital expenditures?
POMDOCTOR LIMITED spent CN¥1.0 million on capital expenditures in fiscal 2025, 0.3% of revenue, compared with CN¥0.0 million the year before.